Kymera Therapeutics (KYMR, Financial) has embarked on the dosing phase of its BroADen Phase 1b clinical trial. This trial is focused on evaluating KT-621, a novel oral treatment aimed at degrading STAT6 in patients suffering from moderate to severe atopic dermatitis.
The company anticipates sharing the trial's findings by the fourth quarter of 2025. In parallel, Kymera has reached a milestone in its KT-621 Phase 1 trial involving healthy volunteers, having completed both single ascending dose (SAD) and multiple ascending dose (MAD) phases, along with follow-up assessments. Results from this segment of the study are expected in June 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Kymera Therapeutics Inc (KYMR, Financial) is $58.33 with a high estimate of $97.00 and a low estimate of $41.00. The average target implies an upside of 114.78% from the current price of $27.16. More detailed estimate data can be found on the Kymera Therapeutics Inc (KYMR) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Kymera Therapeutics Inc's (KYMR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Kymera Therapeutics Inc (KYMR, Financial) in one year is $20.35, suggesting a downside of 25.07% from the current price of $27.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Kymera Therapeutics Inc (KYMR) Summary page.
